NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Scynexis Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Scynexis develops antifungal treatments for severe fungal infections using its proprietary fungerps platform, a novel class of triterpenoid agents targeting difficult-to-treat and drug-resistant pathogens. The company's lead product, ibrexafungerp, was approved for vulvovaginal candidiasis treatment and is now licensed to GSK. A second-generation candidate, SCY-247, is in clinical development for invasive candidiasis and fungal infection prevention in immunocompromised patients.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Scynexis Inc stock.
Slightly undervalued: intrinsic value $3.09 per share, market price $2.85, margin of safety 7.7% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $3.09; the price of $2.85 is 8% below that value.
1 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
7 more in this industry show a wider margin of safety.
SCYX is slightly undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $3.09; the price of $2.85 is 8% below that value.
$3.09 per share (as of the 2026-11-17 close), against a market price of $2.85. That is a margin of safety of 7.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.